Table Graph
      published meta-analysis   sensitivity analysis   studies

antiviral and associated therapy in COVID 19 hospitalized - Summary of results

OutcomeTE95% CInkI2ROBPub. bias deathsdetailed resultsGS-US-540-5773 (Goldman), 2020 0.73 [0.37; 1.44] 0.73[0.37; 1.44]GS-US-540-5773 (Goldman), 202010%397NAnot evaluable clinical improvementdetailed resultsGS-US-540-5773 (Goldman), 2020 0.79 [0.61; 1.02] 0.79[0.61; 1.02]GS-US-540-5773 (Goldman), 202010%397NAnot evaluable clinical improvement (14-day)detailed resultsGS-US-540-5773 (Goldman), 2020 1.53 [1.02; 2.29] 1.53[1.02; 2.29]GS-US-540-5773 (Goldman), 202010%397NAnot evaluable clinical improvement (7-day)detailed resultsGS-US-540-5773 (Goldman), 2020 1.46 [0.95; 2.23] 1.46[0.95; 2.23]GS-US-540-5773 (Goldman), 202010%397NAnot evaluable clinical improvement (time to event analysis only)detailed resultsGS-US-540-5773 (Goldman), 2020 0.79 [0.61; 1.02] 0.79[0.61; 1.02]GS-US-540-5773 (Goldman), 202010%397NAnot evaluable recoverydetailed resultsGS-US-540-5773 (Goldman), 2020 0.81 [0.64; 1.03] 0.81[0.64; 1.03]GS-US-540-5773 (Goldman), 202010%397NAnot evaluable serious adverse events (SAE), anydetailed resultsGS-US-540-5773 (Goldman), 2020 0.50 [0.32; 0.79] 0.50[0.32; 0.79]GS-US-540-5773 (Goldman), 202010%397NAnot evaluable0.22.01.0relative treatment effectwww.metaEvidence.org2024-04-30 11:48 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 95,94,90,91 - treatments: 545,1253,519,619,537,514,688,529,508,656,657,832,530,512,515,754,1142,1419,513,884,632,559,889,956,684,886,631,574,509,542,1145,555,554,941,961,1250,633,676,518,532,510,528,520,955,815,893,623,622,630,593,569,516,814 - roots T: 290

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons